Literature DB >> 9067571

Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.

A Alessandrini1, D S Chiaur, M Pagano.   

Abstract

The cell cycle has been the object of extensive studies for the past years. A complex network of molecular interactions has been identified. In particular, a class of cell cycle inhibitory proteins has been cloned and characterized but details of the molecular mechanism of their action have yet to be resolved. These inhibitors regulate the progression through G1 and the G1/S transition via the inhibition of the cyclin-dependent kinase (Cdk) activity. The potential function of these negative regulators as tumor suppressors provides new insights into the link between the cell cycle and oncogenesis. p27 is a potent inhibitor of Cdks. In quiescent cells p27 accumulates without an increase in mRNA or protein synthesis. Cell cycle regulation of p27 levels, both in normal and transformed human cells, occurs via the ubiquitin-proteasome pathway and, compared to proliferating cells, quiescent cells contain a far lower amount of p27 ubiquitinating activity. The specific proteolysis of p27 is probably involved in the pathway of activation of Cdks. p27 is a phosphoprotein and its phosphorylation is cell cycle regulated. Often phosphorylation is a signal for ubiquitination. p27 is phosphorylated exclusively on serine by Erk1 and almost exclusively on threonine by Cdk1 in in vitro experiments. This finding raises the question of whether and how phosphorylation by these kinases is involved in the process of p27 proteolysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067571     DOI: 10.1038/sj.leu.2400581

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

1.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

Authors:  A Montagnoli; F Fiore; E Eytan; A C Carrano; G F Draetta; A Hershko; M Pagano
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

2.  Noncatalytic requirement for cyclin A-cdk2 in p27 turnover.

Authors:  Xin-Hua Zhu; Hoang Nguyen; H Dorota Halicka; Frank Traganos; Andrew Koff
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

3.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension.

Authors:  S Huang; C S Chen; D E Ingber
Journal:  Mol Biol Cell       Date:  1998-11       Impact factor: 4.138

5.  Adenovirus E1A-regulated transcription factor p120E4F inhibits cell growth and induces the stabilization of the cdk inhibitor p21WAF1.

Authors:  E R Fernandes; J Y Zhang; R J Rooney
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

Review 6.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.

Authors:  H Liu; H Qiu; Y Song; Y Liu; H Wang; M Lu; M Deng; Y Gu; J Yin; K Luo; Z Zhang; X Jia; G Zheng; Z He
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

8.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

9.  Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation.

Authors:  Mathew L Coleman; Christopher J Marshall; Michael F Olson
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

10.  Erk 1,2 phosphorylates p27(Kip1): Functional evidence for a role in high glucose-induced hypertrophy of mesangial cells.

Authors:  G Wolf; R Reinking; G Zahner; R A K Stahl; S J Shankland
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.